SCHEMBL29776805

SCHEMBL29776805

O=c1ccc(-c2cnc(OCC(F)(F)F)nc2)nn1Cc1cccc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 11/20 0.46
▸ PDE4A P27815 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ PDE4C Q08493 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CHEK1 O14757 1/20 0.43
▸ NEK2 P51955 1/20 0.43
▸ LIMK1 P53667 1/20 0.43
▸ TYRO3 Q06418 1/20 0.43
▸ CLK4 Q9HAZ1 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ TP53 P04637 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ GRIN1 Q05586 1/20 0.41
▸ GRIN2B Q13224 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23297298 1.00 MET (0.46) METPDE4APDE4BPDE4CPDE4D
SCHEMBL26627773 0.92 MET (0.44) METPDE4APDE4BPDE4CPDE4D
SCHEMBL26626280 0.90 MET (0.45) METPDE4APDE4BPDE4CPDE4D
SCHEMBL29776791 0.90 MET (0.52) METMEN1KMT2ACHEK1NEK2
SCHEMBL23297321 0.90 MET (0.52) METMEN1KMT2ACHEK1NEK2
SCHEMBL23297285 0.89 PDE4A (0.51) METPDE4APDE4BPDE4CPDE4D
SCHEMBL26999039 0.89 MET (0.46) METPDE4APDE4BPDE4CPDE4D
SCHEMBL23297255 0.88 HDAC1 (0.42) METPDE4APDE4BPDE4CPDE4D
SCHEMBL23528333 0.88 MET (0.40) METPDE4APDE4BPDE4CPDE4D
SCHEMBL26999012 0.88 MET (0.46) METPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240833-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-03-04 — — US disclosed
US-20230048816-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2023-02-16 — — US disclosed
US-11390606-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPECUTICS, INC. (US) 2022-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240833-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MET 4212/4885PDE4A 369/4885PDE4B 627/4885
US-11390606-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MET 4212/4885PDE4A 369/4885PDE4B 627/4885
US-20230048816-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A MET 4212/4885PDE4A 369/4885PDE4B 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback